Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 37Thoracic 20Gastrointestinal 16Tumor-Agnostic 14CNS 7Other solid neoplasm 6Head & Neck 5Other hematologic neoplasm 4Plasma cell 3Breast 3Sarcoma 2Myeloid 2Endocrine 2Gynecologic 1

Conditions

Thyroid Carcinoma, Anaplastic 1Nonseminomatous germ cell tumor 1Neoplasms 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Gastrointestinal Stromal Tumors 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × trametinib × Sarcoma × Clear all
NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡